Navigation Links
Cephalexin in Medical News

Orchid Gets USFDA Nod for Cephalexin

Orchid Chemicals & Pharmaceuticals Ltd today said it has received approval from the USFDA for its ANDA (Abbreviated New Drug Application) of Cephalexin oral suspension. // Cephalexin, an off-patent molecule, forms part of Orchid Chemicals' distribution alliance with US generic pharma major Pa...

Aurobindo gets U.S. FDA approval for Cephalexin

Aurobindo Pharma Ltd has announced that U.S. Food Drug Administration (US FDA) has approved its Cephalexin capsules USP 250 mg & 500 mg.// Cephalexin is used to treat many different types of bacterial infections such as bronchitis, tonsillitis, ear infections, skin infections, and urinary trac...

MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009

... compliance for antibiotics that have been used and trusted by physicians and patients for decades. The Company currently markets the Keflex brand of cephalexin and has received regulatory approval for Moxatag - the first and only once-daily amoxicillin product approved for marketing in the U.S. For more info...

Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas

... compliance for antibiotics that have been used and trusted by physicians and patients for decades. The Company currently markets the Keflex brand of cephalexin and has received regulatory approval for Moxatag -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more inf...

MiddleBrook Pharmaceuticals Reports Third Quarter 2008 Financial Results

...d compliance for antibiotics that have been used and trusted by physicians and patients for decades. The Company currently markets the Keflex brand of cephalexin and has received regulatory approval for Moxatag -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more info...

MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents

...d compliance for antibiotics that have been used and trusted by physicians and patients for decades. MiddleBrook currently markets the Keflex brand of cephalexin and has received regulatory approval for Moxatag -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more info...

MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates

...ddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(R). The Company currently markets the KEFLEX(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) - the first and only once-daily amoxicillin product approved for marketing in the U.S. For more i...

MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results

...ddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(R). The Company currently markets the KEFLEX(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) - the first and only once-daily amoxicillin product approved for marketing in the U.S. For more i...

MiddleBrook to Webcast Management Presentation at the 10th Annual Rodman & Renshaw Healthcare Conference

...ddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(R). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) - the first and only once-daily amoxicillin product approved for marketing in the U.S. For more i...

MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results

...ddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(R). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more ...
Cephalexin in Biological News

Penicillin, amoxicillin: Step aside for strep throat treatment

... Pichichero said. While the newer short-course cephalosporins are only available in brand-name form and are much more expensive, older ones such as cephalexin (better known as Keflex) cost about the same as penicillin or amoxicillin but are more effective against strep. Nearly all drugs fail some of the t...

Gaining ground in the race against antibiotic resistance

...s identified by the group increased the enzyme's efficiency at inactivating cephalexin seven-fold. The mutations influenced the enzyme's active site, where the ch...ut that was not the case here. "This evolved enzyme works better against cephalexin and with the same efficiency on other antibiotics, as well," said Vila. In ...
Cephalexin in Biological Technology

MiddleBrook Pharmaceuticals Hires Key Commercial Team Members

... compliance for antibiotics that have been used and trusted by physicians and patients for decades. The Company currently markets the Keflex brand of cephalexin and has received regulatory approval for Moxatag - the first and only once-daily amoxicillin product approved for marketing in the U.S. For more info...

MiddleBrook Hires TalenTactics to Recruit National Field Force

...ddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(R). The Company currently markets the KEFLEX(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more ...

MiddleBrook Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference

...dleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(TM). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more ...

MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results

...ddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(R). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) - the first and only once-daily amoxicillin product approved for marketing in the U.S. For more o...

MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008

...ddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(R). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more ...

MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008

...dleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(TM). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more ...

MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million

...dleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(TM). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more ...

Innovative Fosshield(R) Antimicrobial Technology Shown to Continuously Kill MRSA 'Superbug'

...of Staphylococcus aureus (staph) resistant to certain antibiotics including methicillin and the more common antibiotics such as oxacillin, penicillin, cephalexin and amoxicillin. MRSA incidence is on the rise in the U.S. and it has now become recognized as a major community-acquired pathogen and growing crisis....
Cephalexin in Biological Definition

Antibiotic

... Beta-lactam ring antibiotics Carbapenems Ertapenem Imipenem Meropenem Cephalosporins and cephamycins cephalexin Cefuroxime Cefadroxil Ceftazidime Monocyclic beta-lactams Penicillins Glycopeptide antibiotics Vancomyci...
Other Tags
(Date:7/29/2015)... ... July 29, 2015 , ... ... the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may ... MOAs to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with ...
(Date:7/29/2015)... ... July 29, 2015 , ... The healthcare ... end user and region. Factors such as the rising pressure to curb healthcare ... and increase in venture capital investments are driving market growth. Check 149 data ...
(Date:7/29/2015)... ... 2015 , ... According to The Spirits Business on July 16th, ... for stimulating and perpetuating alcohol use disorders. Humans have the same gene, which is ... academy of Sciences, and has given researchers inklings to explore Rsu1 in humans to ...
(Date:7/29/2015)... ... July 29, 2015 , ... According to the Miami ... or alcohol addiction and mental health disorders. Acu-detox may begin taking off in the ... from drug and alcohol addiction. Although acupuncture is not a new practice, it is ...
(Date:7/29/2015)... ... July 29, 2015 , ... San Fernando Valley ... Ultherapy. For a limited time only, patients can get the complete treatment process with ... patients who prefer a non-invasive treatment and have loose or sagging skin. , ...
Breaking Medicine News(10 mins):Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 2Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 3Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 4Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 5Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 3Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 2Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 3Health News:San Fernando Valley Dermatology Office, Castle Dermatology Institute, is Now Offering a Promotional Price on Ultherapy 2
(Date:7/20/2015)... 20, 2015  Acuity Market Intelligence,s latest research ... of Commerce and Privacy" forecasts that between 2014 ... will be downloaded to smart mobile devices by ... market is projected to generate more than $67.9 ... seven-year forecast period.    "Biometrics is ...
(Date:7/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), a leading developer ... report financial results for the fourth quarter and fiscal ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-455-2260 (conference ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. ... of human interface solutions, today announced a ... first fully hardware encapsulated fingerprint sensor and ... technology is literally off the grid, isolating ... matching within the fingerprint sensor to provide ...
Breaking Biology News(10 mins):Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
Other Contents